ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO2600

Prepartum 1,3-Butanediol Supplementation Does Not Prevent Onset of Superimposed Preeclampsia in the Dahl S Rat

Session Information

Category: Women’s Health and Kidney Diseases

  • 2000 Women’s Health and Kidney Diseases


  • Ishimwe, Jeanne A., University of Mississippi Medical Center, Jackson, Mississippi, United States
  • Garrett, Michael R., University of Mississippi Medical Center, Jackson, Mississippi, United States
  • Sasser, Jennifer M., University of Mississippi Medical Center, Jackson, Mississippi, United States

Chronic hypertension increases the risk of developing superimposed preeclampsia (PE). Previous reports showed that 1,3-Butanediol (BD) lowers blood pressure (BP) in male Dahl salt sensitive (S) rats and female S.SHR(11) rats. The goal of this study was to test if attenuating hypertension before pregnancy through the placentation period via BD prevents the onset of PE and improves kidney function.


Female Dahl S rats (a spontaneous model of superimposed PE, 11-16 weeks old) were divided into two groups: BD treated (20% via drinking water) and control (ad libitum water). Animals received BD for 7 weeks, baseline BP measurements (telemetry) were taken, and both groups were then mated. On gestation day (GD) 12, treatment was stopped because pilot studies showed that treatment reduced water intake during late pregnancy. Both groups were maintained on normal rodent chow (Teklad 7034, 0.3% NaCl; n=8/group). At GD18 (late pregnancy), uterine artery resistance index (UARI) was measured via Doppler ultrasound, 24h urine was collected on GD19, and tissues were harvested on GD20. Statistical comparisons between groups were done by Student t-test and repeated measures ANOVA used for BP analysis.


Mean arterial pressure was lower in the treated group at baseline (141.9 ± 4.09 vs. 165.7 ± 4.53 mmHg, p= 0.0076), early (135.9 ± 3.42 vs. 168.9 ± 4.55 mmHg, p= 0.0003), mid (142.0 ± 5.16 vs. 170.8 ± 4.61, p= 0.0048) but not late pregnancy (144.9 ± 5.87 vs. 161.9 ± 4.52 mmHg, p= 0.1650). Treated dams had a lower UARI (0.71 ± 0.02 vs. 0.81 ± 0.02, p=0.0077), less fetal resorptions (1.12 ± 0.29 vs. 2.25 ± 0.41, p= 0.0434)) but no differences in pup weight were observed (2.199 ±0.049 vs. 2.199 ± 0.086, p= 0.9938). Proteinuria (39 ± 8 vs. 32 ± 7 mg/day, p=0.5401), blood urea nitrogen (21 ± 0.75 vs. 22 ± 0.78 mg/dL, p=0.2239), creatinine clearance (1.66 ± 0.30 vs. 1.60 ± 0.21 mL/min, p=0.5672) and renal fibrosis (0.55 ± 0.09 vs. 0.75 ±0.08 %, p=0.1382) were unaffected.


In this study, we observed slightly improved placental perfusion and lower fetal demise following prepartum BD treatment; however, the antihypertensive effects of BD were not sustained through late pregnancy when supplementation was stopped at mid-pregnancy. No improvements in renal function were noted.